Calithera Biosciences Inc (CALA) Given Consensus Recommendation of “Hold” by Analysts
Shares of Calithera Biosciences Inc (NASDAQ:CALA) have received a consensus rating of “Hold” from the eight research firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $16.75.
A number of research firms have recently weighed in on CALA. ValuEngine lowered Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 3rd. BidaskClub lowered Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 18th. Finally, Zacks Investment Research lowered Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd.
Calithera Biosciences (CALA) traded up $0.17 during midday trading on Tuesday, hitting $7.07. The stock had a trading volume of 533,191 shares, compared to its average volume of 458,889. Calithera Biosciences has a 12 month low of $6.57 and a 12 month high of $20.05. The company has a market cap of $251.00, a price-to-earnings ratio of -7.14 and a beta of 2.56.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.